サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1426230

経口バイオロジックおよびバイオシミラー医薬品の世界市場レポート 2024

Oral Biologics & Biosimilar Drugs Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
経口バイオロジックおよびバイオシミラー医薬品の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

経口バイオロジックおよびバイオシミラー医薬品の市場規模は、今後数年間で急激に成長すると予想されます。 2028年には16.7%の年間複合成長率（CAGR）で133億2,000万米ドルに成長すると予想されます。予測期間における予想される成長は、特に標的療法の拡大、予防医学の重視の高まり、ヘルスケア費の増加、人口の高齢化など、いくつかの要因によって推進されます。この期間中に予想される主な動向には、経口送達技術の進歩、経口投与される生物製剤の開発、バイオシミラーの革新的な進歩、患者中心のケアモデルへの移行が含まれます。

関節炎、喘息、がんなどの慢性疾患の蔓延により、経口生物製剤およびバイオシミラー市場の成長が促進されると予想されます。労働時間の延長、身体活動の制限、不健康な食生活などの要因が慢性疾患の増加に寄与しており、その治療に生物学的製剤がますます利用されています。これらの薬剤は、がん細胞と戦う免疫系を刺激し、がん細胞の排除を助けます。国連は、2030年までに世界の死亡の約70%が慢性疾患に起因し、これらの疾患による世界の負担は約60%に達すると予測しています。その結果、慢性疾患の急増により生物製剤およびバイオシミラーの需要が高まり、経口バイオロジックおよびバイオシミラー医薬品市場の成長が促進されると予想されます。

個別化医療に対する需要の高まりにより、経口バイオロジックおよびバイオシミラー医薬品市場の成長が促進されると考えられます。個別化医療には、医療上の決定と薬物療法を個々の患者に合わせて調整することが含まれます。このアプローチは経口生物学的製剤およびバイオシミラーの開発と利用に沿ったもので、副作用を最小限に抑えながら治療効果を最適化し、試行錯誤方法を減らし、より高い奏効率と生存期間の延長につながります。 2022年10月のSTATのレポートでは、75,000を超える遺伝子検査製品と300の個別化医療が示されており、個別化医療に対する需要の増加が腫瘍分子診断市場の成長を促進していることが浮き彫りになっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の経口バイオロジックおよびバイオシミラー医薬品市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • リンパ球モジュレーター
  • インターロイキン阻害剤
  • 腫瘍壊死因子アルファ阻害剤
  • 世界の経口バイオロジックおよびバイオシミラー医薬品市場、疾患別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 喘息
  • クローン病
  • がん腫
  • 関節炎
  • 糖尿病
  • 多発性骨髄腫
  • 腸炎
  • 多発性硬化症
  • 肉腫
  • 乾癬およびその他
  • 世界の経口バイオロジックおよびバイオシミラー医薬品市場、分子タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ワクチン
  • タンパク質とペプチド
  • モノクローナル抗体
  • 他の分子タイプ
  • 世界の経口バイオロジックおよびバイオシミラー医薬品市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域および国の分析

  • 世界の経口バイオロジックおよびバイオシミラー医薬品市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の経口バイオロジックおよびバイオシミラー医薬品市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 経口バイオロジックおよびバイオシミラー医薬品市場の競合情勢
  • 経口バイオロジックおよびバイオシミラー医薬品市場の企業プロファイル
    • Novartis International AG
    • Rani Therapeutics Holdings Inc.
    • Eli Lilly and Company
    • AstraZeneca plc
    • Novo Nordisk A/S

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r13252

A biosimilar is a medication designed to closely resemble a biologic drug both structurally and functionally. Biologic drugs are treatments produced using biological systems like yeast, bacteria, or animal cells. A biological product is deemed 'biosimilar' if it closely matches an FDA-approved reference product with no clinically discernible differences.

Within therapy types, there are oral biologics and biosimilars categorized as lymphocyte modulators, interleukin inhibitors, and tumor necrosis factor-alpha inhibitors. Interleukin inhibitors are immunosuppressive drugs that hinder interleukins' functionality. Interleukins are a group of cytokines generated by lymphocytes, monocytes, macrophages, and various other cells, crucial in regulating the immune system. These drugs treat various conditions such as asthma, Crohn's disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis, and others. They are available in forms like vaccines, proteins, peptides, monoclonal antibodies, distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The oral biologics and biosimilar market research report is one of a series of new reports from The Business Research Company that provides oral biologics and biosimilar market statistics, including oral biologics and biosimilar industry global market size, regional shares, competitors with an oral biologics and biosimilar market share, detailed oral biologics and biosimilar market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics and biosimilar industry. This oral biologics and biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oral biologics & biosimilar drugs market size has grown exponentially in recent years. It will grow from $5.94 billion in 2023 to $7.19 billion in 2024 at a compound annual growth rate (CAGR) of 21.0%. The growth observed in the historical period can be attributed to several factors, including an increased prevalence of chronic diseases, heightened awareness surrounding oral biologics, the expiration of patents on existing medications, and an escalating demand for biosimilars.

The oral biologics & biosimilar drugs market size is expected to see exponentially grown in the next few years. It will grow to $13.32 billion in 2028 at a compound annual growth rate (CAGR) of 16.7%. Anticipated growth in the forecast period is driven by several factors, notably the expansion of targeted therapy, a growing emphasis on preventive medicine, increased healthcare expenditures, and an aging population. Major trends expected during this period encompass advancements in oral delivery technology, the development of orally administered biologics, innovative strides in biosimilars, and a shift towards patient-centric care models.

The prevalence of chronic conditions like arthritis, asthma, and cancer is anticipated to drive growth in the oral biologics and biosimilar market. Factors such as extended work hours, limited physical activity, and unhealthy dietary habits contribute to the rise in chronic diseases, and biologics are increasingly utilized for their treatment. These medications trigger the immune system to combat cancer cells, aiding in their elimination. The United Nations projects that by 2030, about 70% of global deaths will be attributed to chronic diseases, with the global burden of these conditions expected to reach approximately 60%. Consequently, the surge in chronic diseases is expected to fuel demand for biologics and biosimilars, spurring growth in the oral biologics and biosimilar drugs market.

The escalating demand for personalized medicine is set to propel growth in the oral biologics and biosimilar drugs market. Personalized medicine involves tailoring medical decisions and drug therapies to individual patients. This approach aligns with the development and utilization of oral biologics and biosimilars, optimizing treatment efficacy while minimizing side effects and reducing trial-and-error methods, leading to higher response rates and extended survival. Reports by STAT in October 2022 indicated over 75,000 genetic testing products and 300 personalized medicines, underscoring the increasing demand for personalized medicine driving growth in the oncology molecular diagnostics market.

A noteworthy trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. Key market players are investing in developing biosimilar versions of insulin, fostering competition among different biosimilar manufacturers. For instance, in April 2023, Eli Lilly and Company introduced Rezvoglar (insulin glargine-aglr), a biosimilar of insulin glargine used for improving glycemic control in adults, children, and infants with type 1 diabetes, as well as adults with type 2 diabetes.

Major players in the oral biologics and biosimilar market are concentrating on innovative products like interchangeable biosimilars to drive market revenues. Interchangeable biosimilars meet specific regulatory requirements, allowing them to be substituted for the reference biologic product without the intervention of the prescribing healthcare provider. For example, in November 2021, Viatris Inc. and Biocon Biologics Limited launched SEMGLEE (insulin glargine-yfgn) injection and Insulin Glargine (insulin glargine-yfgn) injection. These interchangeable biosimilars aid adults with type 2 diabetes and children with type 1 diabetes in managing high blood sugar, substituting for the reference brand LANTUS (insulin glargine) and available in vial and prefilled pen formats for pharmacy counter substitution.

Major companies operating in the oral biologics & biosimilar drugs market include Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca PLC, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan PLC, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, Ganlee Corporation, 3SBio Inc., Innovent Biologics Inc., Retractable Technologies Inc., Changchun High & New Technology Industries (Group) Inc., Dong Bao Pharmaceutical Co. Ltd., CP Guojian Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, Concord Biotech Limited, Aurobindo Pharma Limited, H. Lundbeck A/S, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.

North America was the largest region in the oral biologics and biosimilar drugs market in 2023. The Middle East is expected to be the fastest growing region in the oral biologics & biosimilar drugs market report during the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oral biologics and biosimilar market consist of sales of therapeutic proteins, cystic fibrosis, somatic cells, and allergenics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Biologics & Biosimilar Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral biologics & biosimilar drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral biologics & biosimilar drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral biologics & biosimilar drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors
  • 2) By Disease: Asthma; Crohn's Disease; Carcinoma; Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Sarcoma; Psoriasis and Others
  • 3) By Molecule Type: Vaccines; Proteins & Peptides; Monoclonal Antibodies; Other Molecule Types
  • 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
  • Companies Mentioned: Novartis International AG; Rani Therapeutics Holdings Inc.; Eli Lilly and Company; AstraZeneca plc; Novo Nordisk A/S
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Oral Biologics & Biosimilar Drugs Market Characteristics

3. Oral Biologics & Biosimilar Drugs Market Trends And Strategies

4. Oral Biologics & Biosimilar Drugs Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Oral Biologics & Biosimilar Drugs Market Size and Growth

  • 5.1. Global Oral Biologics & Biosimilar Drugs Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Oral Biologics & Biosimilar Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Oral Biologics & Biosimilar Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Oral Biologics & Biosimilar Drugs Market Segmentation

  • 6.1. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Lymphocyte Modulators
  • Interleukin Inhibitors
  • Tumor Necrosis Factor-Alpha Inhibitors
  • 6.2. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Asthma
  • Crohn's Disease
  • Carcinoma
  • Arthritis
  • Diabetes
  • Multiple Myeloma
  • Enterocolitis
  • Multiple Sclerosis
  • Sarcoma
  • Psoriasis and Others
  • 6.3. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Vaccines
  • Proteins & Peptides
  • Monoclonal Antibodies
  • Other Molecule Types
  • 6.4. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Oral Biologics & Biosimilar Drugs Market Regional And Country Analysis

  • 7.1. Global Oral Biologics & Biosimilar Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Oral Biologics & Biosimilar Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Oral Biologics & Biosimilar Drugs Market

  • 8.1. Asia-Pacific Oral Biologics & Biosimilar Drugs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Oral Biologics & Biosimilar Drugs Market

  • 9.1. China Oral Biologics & Biosimilar Drugs Market Overview
  • 9.2. China Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Oral Biologics & Biosimilar Drugs Market

  • 10.1. India Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Oral Biologics & Biosimilar Drugs Market

  • 11.1. Japan Oral Biologics & Biosimilar Drugs Market Overview
  • 11.2. Japan Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Oral Biologics & Biosimilar Drugs Market

  • 12.1. Australia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Oral Biologics & Biosimilar Drugs Market

  • 13.1. Indonesia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Oral Biologics & Biosimilar Drugs Market

  • 14.1. South Korea Oral Biologics & Biosimilar Drugs Market Overview
  • 14.2. South Korea Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Oral Biologics & Biosimilar Drugs Market

  • 15.1. Western Europe Oral Biologics & Biosimilar Drugs Market Overview
  • 15.2. Western Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Oral Biologics & Biosimilar Drugs Market

  • 16.1. UK Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Oral Biologics & Biosimilar Drugs Market

  • 17.1. Germany Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Oral Biologics & Biosimilar Drugs Market

  • 18.1. France Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Oral Biologics & Biosimilar Drugs Market

  • 19.1. Italy Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Oral Biologics & Biosimilar Drugs Market

  • 20.1. Spain Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Oral Biologics & Biosimilar Drugs Market

  • 21.1. Eastern Europe Oral Biologics & Biosimilar Drugs Market Overview
  • 21.2. Eastern Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Oral Biologics & Biosimilar Drugs Market

  • 22.1. Russia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Oral Biologics & Biosimilar Drugs Market

  • 23.1. North America Oral Biologics & Biosimilar Drugs Market Overview
  • 23.2. North America Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Oral Biologics & Biosimilar Drugs Market

  • 24.1. USA Oral Biologics & Biosimilar Drugs Market Overview
  • 24.2. USA Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Oral Biologics & Biosimilar Drugs Market

  • 25.1. Canada Oral Biologics & Biosimilar Drugs Market Overview
  • 25.2. Canada Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Oral Biologics & Biosimilar Drugs Market

  • 26.1. South America Oral Biologics & Biosimilar Drugs Market Overview
  • 26.2. South America Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Oral Biologics & Biosimilar Drugs Market

  • 27.1. Brazil Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Oral Biologics & Biosimilar Drugs Market

  • 28.1. Middle East Oral Biologics & Biosimilar Drugs Market Overview
  • 28.2. Middle East Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Oral Biologics & Biosimilar Drugs Market

  • 29.1. Africa Oral Biologics & Biosimilar Drugs Market Overview
  • 29.2. Africa Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Oral Biologics & Biosimilar Drugs Market Competitive Landscape And Company Profiles

  • 30.1. Oral Biologics & Biosimilar Drugs Market Competitive Landscape
  • 30.2. Oral Biologics & Biosimilar Drugs Market Company Profiles
    • 30.2.1. Novartis International AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Rani Therapeutics Holdings Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Eli Lilly and Company
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AstraZeneca plc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novo Nordisk A/S
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Oral Biologics & Biosimilar Drugs Market Competitive Benchmarking

32. Global Oral Biologics & Biosimilar Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Oral Biologics & Biosimilar Drugs Market

34. Oral Biologics & Biosimilar Drugs Market Future Outlook and Potential Analysis

  • 34.1 Oral Biologics & Biosimilar Drugs Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Oral Biologics & Biosimilar Drugs Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Oral Biologics & Biosimilar Drugs Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer